AstraZeneca Canada and Bristol-Myers Squibb Canada Invest $500,000 In
Strategy to Benefit Canadians Living with Diabetes
LONDON, ON, Sept. 2 /CNW/ - Research being driven by The University of
Western Ontario that will enhance diabetes management across Canada recently
received support from two of Canada's leading pharmaceutical companies in the
form of a $500,000 contribution. As part of a joint venture initiative,
AstraZeneca Canada and Bristol-Myers Squibb Canada announced the donation that
will support the National Diabetes Management Strategy (the Strategy), a
research partnership between The University of Western Ontario and the
Canadian Diabetes Association.
"This funding will allow researchers to develop and evaluate
evidence-based models of care to close gaps in diabetes management," explained
Ellen Malcolmson, President and CEO, Canadian Diabetes Association. "In
particular, the funding will help target challenges affecting family
physicians and healthcare providers at the primary level who are delivering
care to the majority of diabetes patients in the system."
The Strategy will focus on the Canadian Diabetes Association 2008
Clinical Practice Guidelines for the Prevention and Management of Diabetes in
Canada and identify success factors and barriers to family practice
implementation. Researchers will also address professional education for
family practitioners and healthcare professionals.
"Diabetes ranks third in most frequently diagnosed diseases by family
physicians in Canada," said Dr. Stewart Harris, lead investigator for the
Strategy who holds the Canadian Diabetes Association Chair in Diabetes
Management at the Schulich School of Medicine & Dentistry. "In the decade
spanning 1995 to 2005, incidence of diabetes in adults skyrocketed 113 per
cent while the population rose modestly by 17 per cent in comparison. By
supporting the Strategy, AstraZeneca Canada and Bristol-Myers Squibb Canada
reinforce the urgency to advance management and prevention."
"The objectives of the National Diabetes Strategy are aligned with
AstraZeneca's commitment to improve the lives of Canadians," said Catriona
McMahon, Vice President Medical Affairs, AstraZeneca Canada. "We are proud to
support a project that directs resources to family doctors and healthcare
providers who are burdened with mounting patient volumes and increasingly
complex diabetes cases."
Diabetes and its complications can seriously impact quality of life and
bring devastating consequences to patients, including kidney problems, nerve
damage, heart disease and blindness. When managed effectively, however,
patients with diabetes can minimize risks and lead healthy lives.
"Ensuring the success of a national strategy for diabetes requires the
support and collaboration of many stakeholders - government, the
pharmaceutical industry and the medical community," said Dr. Mitch Shulman,
Vice President Medical Affairs, Bristol-Myers Squibb Canada. "We're pleased to
be contributing to this important initiative that has the potential to make a
tremendous difference for the millions of Canadians living with diabetes."
Dr. Stewart Harris is a Professor at Western's Schulich School of
Medicine & Dentistry with appointments in Family Medicine, Endocrinology &
Metabolism and Epidemiology & Biostatistics. Harris also hold the Ian
McWhinney Chair in Family Medicine Studies and is a scientist at the Lawson
Health Research Institute.
About the Canadian Diabetes Association
The Canadian Diabetes Association works in communities across the country
to promote the health of Canadians and eliminate diabetes through our strong
nationwide network of volunteers, employees, healthcare professionals,
researchers, partners and supporters. In the struggle against this global
epidemic, our expertise is recognized around the world. For more information,
please visit diabetes.ca or call 1-800-BANTING (226-8464).
AstraZeneca is a major international healthcare business engaged in the
research, development, manufacturing and marketing of meaningful prescription
medicines and supplier for healthcare services. AstraZeneca is one of the
world's leading pharmaceutical companies with healthcare sales of US$ 31.6
billion and is a leader in gastrointestinal, cardiovascular, neuroscience,
respiratory, oncology and infectious disease medicines. For more information
about AstraZeneca, please visit: www.astrazeneca.ca.
About Bristol-Myers Squibb Canada
Bristol-Myers Squibb Canada is an indirect wholly-owned subsidiary of
Bristol-Myers Squibb Company, a global pharmaceutical and related healthcare
products company whose mission is to extend and enhance human life.
Bristol-Myers Squibb Canada is a leading provider of medicines to fight
cancer, cardiovascular and metabolic disorders, infectious diseases (including
HIV/AIDS), nervous system diseases and serious mental illness. Bristol-Myers
Squibb Company is listed on the New York Stock Exchange under the BMY symbol
(NYSE: BMY). Bristol-Myers Squibb Canada's operations are headquartered in
About The University of Western Ontario
The University of Western Ontario is a leader in diabetes research - a
strength that dates back to 1921 when Sir Frederick Banting was an instructor
at the University.
For further information:
For further information: Jeremy Brace, Canadian Diabetes Association,
(416) 408-7071, E-mail: firstname.lastname@example.org; Morgan Cates,
Fleishman-Hillard Canada, (416) 645-8201, E-mail: email@example.com;
Ann Hutchison, The University of Western Ontario, (519) 661-2111 ext. 85468,
Email: firstname.lastname@example.org; Marc Osborne, Bristol-Myers Squibb Canada, (514)
333-2465, E-mail: email@example.com; Lee Rammage, AstraZeneca Canada, (905)
804-4913, E-mail: firstname.lastname@example.org